NCT07047612

ICP-332 in Subjects With Non-segmental Vitiligo

A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 603 (estimated)
• Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Industry
• Sex: All
• Age: 12 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an phase 2 part and an phase 3 part.

Conditions

• Non Segmental Vitiligo

Interventions

Type	Name	Description
DRUG	ICP-332 Tablets	ICP-332 will be administered as tablet
DRUG	ICP-332 Placebo Tablets	ICP-332 Placebo will be administered as tablet

Timeline

• Start date: 2025-05-09
• Primary completion: 2029-04-01
• Completion: 2029-04-01
• First posted: 2025-07-02
• Last updated: 2025-08-07

Locations

45 sites across 1 country: China